AI-Driven Drug Development - BullFrog AI Expands Licensing Deal With Johns Hopkins Applied Physics Laboratory - Bullfrog AI Hldgs (NASDAQ:BFRG)

BullFrog AI Holdings, Inc. BFRG announced the expansion of its worldwide license agreement with the Johns Hopkins Applied Physics Laboratory (APL) in Laurel, Maryland.
The license expansion is for using the patented technology powering the company's AI-driven bfLEAP platform, which analyzes drug development data to make life-saving therapies and treatments.
bfLEAP is used for several critical stages of therapeutics development to streamline data analytics, decreasing the overall development costs.
The patented technology from APL powering bfLEAP includes analytical models that interpret large, complex, and diverse datasets to provide explainable results.
The latest license improvements will also enable bfLEAP to be much more robust, both from a software perspective and mathematically.
"Our expanded license with APL is a testament to our relentless pursuit of innovation, enabling us to harness the full potential of AI in accelerating the development of life-saving therapies," said Vin Singh, Founder and CEO of BullFrog AI.
"This breakthrough technology not only has the potential to disrupt the industry, but also transform countless lives across the globe," Singh added.
Price Action: BFRG shares are trading higher by 2.97% to $4.85 on the last check Monday.

AI-Driven Drug Development - BullFrog AI Expands Licensing Deal With Johns Hopkins Applied Physics Laboratory